Unraveling the genetic determinants of small vessel vasculitis

November 03, 2020

Tsukuba, Japan - Autoimmune disease is fundamentally a mystery: whyever should an organism systematically set out to harm itself? Now, researchers at the University of Tsukuba have identified a genetic basis for anti-neutrophil cytoplasmic antibody (ANCA)-associated vasculitis, an autoimmune systemic disease that damages organs by targeting small blood vessels in a genetic association study. Interestingly, these specific gene variants, though previously known to increase risk for idiopathic pulmonary fibrosis (IPF), appear to be unassociated with the morbid complication called interstitial lung disease (ILD).

ANCA-associated vasculitis (AAV) is a group of diseases in which neutrophils tag small blood vessels as foreign and attack them throughout the body, causing inflammatory damage. The most affected organs include the kidney and lung, though the reasons underlying this self-inflicted assault remain unclear.

Of the various subtypes of AAV, microscopic polyangiitis (MPA) and myeloperoxidase (MPO)-ANCA positive AAV (MPO-AAV) are more common in Asian populations and more associated with the severe complication AAV-associated ILD (AAV-ILD). Notably, even within the MPA subset, more ILD is seen in Japanese than in Europeans, suggesting a genetic predisposition.

Professor Aya Kawasaki, lead author, clarified the research background. "We had previously reported that a MUC5B gene variant linked to IPF was increased only in AAV patients with ILD. However, its rarity among Japanese made us suspect other IPF susceptibility alleles in TERT and DSP genes."

The research team classified AAV patients into subsets. MPO-AAV patients were further categorized into those with ILD and those without, based on CT. Genotypes of TERT and DSP were determined for patients and controls, and analyzed. "We found that the frequency of IPF risk alleles TERT and DSP were significantly increased in MPA and MPO-AAV," explains Professor Kawasaki. "However, the allele frequencies in MPO-AAV were similar regardless of associated ILD. We concluded that TERT and DSP IPF risk alleles were associated with MPA and MPO-AAV irrespective of concomitant ILD, and may be novel susceptibility genes for both AAV subtypes. Additionally, the genetic predisposition for these conditions and IPF may overlap." (Figure)

"Factoring these epidemiological and genetic differences between European and East Asian populations will broaden our knowledge base of rare diseases such as AAV," says Professor Naoyuki Tsuchiya, senior author. "Pinpointing the risk alleles and elucidating the underlying molecular mechanisms would not only lead to better understanding of the etiopathogenesis of these conditions, but also help identify new molecular targets for treatment of related autoimmune diseases."
-end-
The article, "Association of TERT and DSP variants with microscopic polyangiitis and myeloperoxidase-ANCA positive vasculitis in a Japanese population: a genetic association study" was published in Arthritis Research & Therapy at DOI: https://doi.org/10.1186/s13075-020-02347-0

University of Tsukuba

Related Idiopathic Pulmonary Fibrosis Articles from Brightsurf:

Researchers identify better classification system for adult idiopathic scoliosis
Researchers have designed a new X-ray classification system for adult idiopathic scoliosis that can more precisely define which parts of the spine need correction

The CNIO pave the way for a future gene therapy to reverse pulmonary fibrosis associated with ageing
''Our results indicate that a new therapy may be developed to prevent the development of pulmonary fibrosis associated with ageing,'' says CNIO's Maria Blasco, principal investigator of the study * Lung tissue of patients with pulmonary fibrosis does not regenerate because the cells involved in lung generation have damaged telomeres, the ends of the chromosomes.

Pulmonary fibrosis treatment shows proof of principle
A pre-clinical study led by scientists at Cincinnati Children's demonstrates that in mice the drug barasertib reverses the activation of fibroblasts that cause dangerous scar tissue to build up in the lungs of people with idiopathic pulmonary fibrosis (IPF).

Stem cells from placental amniotic membrane slow lung scarring in pulmonary fibrosis
In a study released today in STEM CELLS Translational Medicine (SCTM), researchers show for the first time how stem cells collected from human amniotic membrane can slow the progression of scarring in pulmonary fibrosis.

Researchers identify key mechanisms involved in pulmonary fibrosis development
Working alongside research groups from Heidelberg, researchers from Charité - Universitätsmedizin Berlin have elucidated the novel disease processes involved in the development of pulmonary fibrosis.

Bacterial protein fragment kills lung cells in pulmonary fibrosis, study finds
A bacterial protein fragment instigates lung tissue death in pulmonary fibrosis, a mysterious disease affecting millions of people worldwide, according to a new study from researchers at the University of Illinois at Urbana-Champaign and Mie University in Japan.

Closing in on liver fibrosis: Detailing the fibrosis process at unprecedented resolution
Today, there is no effective way to treat liver fibrosis.

Inhalation therapy shows promise against pulmonary fibrosis in mice, rats
A new study shows that lung stem cell secretions -- specifically exosomes and secretomes -- delivered via nebulizer, can help repair lung injuries due to multiple types of pulmonary fibrosis in mice and rats.

Cystic fibrosis carriers are at increased risk for cystic fibrosis-related conditions
A University of Iowa study challenges the conventional wisdom that having just one mutated copy of the cystic fibrosis (CF) gene has no effects on a person's health.

Short or long sleep associated with Pulmonary Fibrosis
Scientists have discovered that people who regularly sleep for more than 11 hours or less than 4 hours are 2-3 times more likely to have the incurable disease, pulmonary fibrosis, compared to those that sleep for 7 hours in a day.

Read More: Idiopathic Pulmonary Fibrosis News and Idiopathic Pulmonary Fibrosis Current Events
Brightsurf.com is a participant in the Amazon Services LLC Associates Program, an affiliate advertising program designed to provide a means for sites to earn advertising fees by advertising and linking to Amazon.com.